CoChat

Evaluation of Female Fertility—AMH and Ovarian Reserve Testing

Open access
Cedars, Marcelle I · 2022 · The Journal of Clinical Endocrinology & Metabolism
Cited by 208

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Context: Evaluation of the infertile female requires an understanding of ovulation and biomarkers of ovarian reserve. Antimüllerian hormone (AMH) correlates with growing follicles in a menstrual cycle. Increasingly, AMH has been used as a “fertility test.” This narrative review describes how to integrate the use of AMH into diagnosis and treatment. Methods: A PubMed search was conducted to find recent literature on measurements and use of serum AMH as a marker of ovarian reserve and in treatment of infertility. Results: Serum AMH estimates ovarian reserve, helps determine dosing in ovarian stimulation, and predicts stimulation response. As such, AMH is a good marker of oocyte quantity but does not reflect oocyte health or chances for pregnancy. Screening of AMH before fertility treatment should be used to estimate expected response and not to withhold treatment. Low AMH levels may suggest a shortened reproductive window. AMH levels must be interpreted in the context of the endogenous endocrine environment where low follicle-stimulating hormone, due to hypogonadotropic hypogonadism or hormonal contraceptive use, may lower AMH without being a true reflection of ovarian reserve. In addition, there is an inverse correlation between body mass index and AMH that does not reflect ovarian response. Conclusion: AMH is a useful marker of ovarian reserve in reproductive-aged women. Increased screening of noninfertile women requires a thorough knowledge of situations that may affect AMH levels. In no situation does AMH reflect oocyte health or chances for conception. Age is still the strongest driver in determining success rates with fertility treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgac039

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 82

  1. Practice Committee of the American Society for Reproductive Medicine., 2013, Definitions of infertility and recurrent pregnancy loss: a committee opinion, Fertil Steril., 99, 63, 10.1016/j.fertnstert.2012.09.023 · DOI · Paper page
  2. Matthews, 2014, First births to older women continue to rise, NCHS Data Brief., 1
  3. Fischer, 2020, Commentary: management strategies for POSEIDON Groups 3 and 4, Front Endocrinol (Lausanne)., 11, 34, 10.3389/fendo.2020.00034 · doi:10.3389/fendo.2020.00034
  4. Pellestor, 2006, The occurrence of aneuploidy in human: lessons from the cytogenetic studies of human oocytes, Eur J Med Genet., 49, 103, 10.1016/j.ejmg.2005.08.001 · DOI · Paper page
  5. Kelsey, 2011, A validated model of serum anti-müllerian hormone from conception to menopause, PLoS One., 6, e22024, 10.1371/journal.pone.0022024 · DOI · Paper page
  6. Rosen, 2012, A characterization of the relationship of ovarian reserve markers with age, Fertil Steril., 97, 238, 10.1016/j.fertnstert.2011.10.031 · DOI · Paper page
  7. Cramer, 1995, Family history as a predictor of early menopause, Fertil Steril., 64, 740, 10.1016/S0015-0282(16)57849-2 · DOI · Paper page
  8. de Bruin, 2001, The role of genetic factors in age at natural menopause, Hum Reprod., 16, 2014, 10.1093/humrep/16.9.2014 · DOI · Paper page
  9. Murabito, 2005, Heritability of age at natural menopause in the Framingham Heart Study, J Clin Endocrinol Metab., 90, 3427, 10.1210/jc.2005-0181 · DOI · Paper page
  10. Rosen, 2010, Antral follicle count: absence of significant midlife decline, Fertil Steril., 94, 2182, 10.1016/j.fertnstert.2009.12.045 · DOI · Paper page
  11. Bentzen, 2013, Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age, Hum Reprod., 28, 247, 10.1093/humrep/des356 · DOI
  12. Hansen, 2011, Correlation of ovarian reserve tests with histologically determined primordial follicle number, Fertil Steril., 95, 170, 10.1016/j.fertnstert.2010.04.006 · DOI · Paper page
  13. Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Reproductive Endocrinology and Infertility, 2017, Optimizing natural fertility: a committee opinion, Fertil Steril., 107, 52, 10.1016/j.fertnstert.2016.09.029 · DOI
  14. Ethics Committee of the American Society for Reproductive Medicine, 2013, Disposition of abandoned embryos: a committee opinion, Fertil Steril., 99, 1848, 10.1016/j.fertnstert.2013.02.024 · doi:10.1016/j.fertnstert.2013.02.024
  15. Harris, 2021, Ovarian reserve biomarkers and menstrual cycle length in a prospective cohort study, J Clin Endocrinol Metab., 106, e3748, 10.1210/clinem/dgab204 · DOI
  16. Vassena, 2014, Menstrual cycle length in reproductive age women is an indicator of oocyte quality and a candidate marker of ovarian reserve, Eur J Obstet Gynecol Reprod Biol., 177, 130, 10.1016/j.ejogrb.2014.03.027 · DOI
  17. Younis, 2020, Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? a systematic review and meta-analysis, Hum Reprod Update., 26, 904, 10.1093/humupd/dmaa013 · DOI
  18. Mersereau, 2008, Preimplantation genetic screening to improve in vitro fertilization pregnancy rates: a prospective randomized controlled trial, Fertil Steril., 90, 1287, 10.1016/j.fertnstert.2007.08.010 · DOI
  19. Pal, 2010, Characterizing the reproductive hormone milieu in infertile women with diminished ovarian reserve, Fertil Steril., 93, 1074, 10.1016/j.fertnstert.2008.10.069 · DOI
  20. Pfister, 2019, Association between diminished ovarian reserve and luteal phase deficiency, Fertil Steril., 112, 378, 10.1016/j.fertnstert.2019.03.032 · doi:10.1016/j.fertnstert.2019.03.032
  21. Broekmans, 2010, The antral follicle count: practical recommendations for better standardization, Fertil Steril., 94, 1044, 10.1016/j.fertnstert.2009.04.040 · DOI · Paper page
  22. von Wolff, 2020, Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve, Maturitas., 134, 34, 10.1016/j.maturitas.2020.02.001 · DOI
  23. Streuli, 2008, Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids, Fertil Steril., 90, 395, 10.1016/j.fertnstert.2007.06.023 · DOI · Paper page
  24. Steiner, 2017, Association between biomarkers of ovarian reserve and infertility among older women of reproductive age, JAMA., 318, 1367, 10.1001/jama.2017.14588 · DOI · Paper page
  25. Zarek, 2015, Is anti-Müllerian hormone associated with fecundability? findings from the EAGeR trial, J Clin Endocrinol Metab., 100, 4215, 10.1210/jc.2015-2474 · DOI
  26. Depmann, 2017, Anti-Müllerian hormone does not predict time to pregnancy: results of a prospective cohort study, Gynecol Endocrinol., 33, 644, 10.1080/09513590.2017.1306848 · DOI
  27. Broer, 2010, The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome, Curr Opin Obstet Gynecol., 22, 193, 10.1097/GCO.0b013e3283384911 · DOI
  28. Broer, 2013, Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach, Hum Reprod Update., 19, 26, 10.1093/humupd/dms041 · DOI · Paper page
  29. Iliodromiti, 2014, The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature, Hum Reprod Update., 20, 560, 10.1093/humupd/dmu003 · DOI · Paper page
  30. Granger, 2019, Anti-Müllerian hormone and its predictive utility in assisted reproductive technologies outcomes, Clin Obstet Gynecol., 62, 238, 10.1097/GRF.0000000000000436 · doi:10.1097/grf.0000000000000436
  31. La Marca, 2012, Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles, BJOG., 119, 1171, 10.1111/j.1471-0528.2012.03412.x · doi:10.1111/j.1471-0528.2012.03412.x
  32. Hendriks, 2005, Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level, Fertil Steril., 83, 291, 10.1016/j.fertnstert.2004.10.011 · DOI · Paper page
  33. Iliodromiti, 2015, Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response, Hum Reprod Update., 21, 698, 10.1093/humupd/dmu062 · DOI · Paper page
  34. La Marca, 2010, Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART), Hum Reprod Update., 16, 113, 10.1093/humupd/dmp036 · DOI · Paper page
  35. Polyzos, 2013, Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection, Fertil Steril., 100, 430, 10.1016/j.fertnstert.2013.04.029 · doi:10.1016/j.fertnstert.2013.04.029
  36. Neves, 2020, The performance of the Elecsys anti-Müllerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa, Reprod Biomed Online., 41, 29, 10.1016/j.rbmo.2020.03.023 · DOI
  37. Esteves, 2021, Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients, Hum Reprod., 36, 1530, 10.1093/humrep/deab056 · DOI
  38. Tomas, 1997, Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization, Hum Reprod., 12, 220, 10.1093/humrep/12.2.220 · DOI
  39. Chang, 1998, Use of the antral follicle count to predict the outcome of assisted reproductive technologies, Fertil Steril., 69, 505, 10.1016/S0015-0282(97)00557-8 · DOI · Paper page
  40. Hsu, 2011, Antral follicle count in clinical practice: analyzing clinical relevance, Fertil Steril., 95, 474, 10.1016/j.fertnstert.2010.03.023 · doi:10.1016/j.fertnstert.2010.03.023
  41. Tsakos, 2014, Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET, Arch Gynecol Obstet., 290, 1249, 10.1007/s00404-014-3332-3 · DOI
  42. Blazar, 2011, Use of in-cycle antimüllerian hormone levels to predict cycle outcome, Am J Obstet Gynecol., 205, 223.e1, 10.1016/j.ajog.2011.04.035 · DOI
  43. Nardo, 2009, The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome, Hum Reprod., 24, 2917, 10.1093/humrep/dep225 · DOI · Paper page
  44. La Marca, 2012, Possibilities and limits of ovarian reserve testing in ART, Curr Pharm Biotechnol., 13, 398, 10.2174/138920112799361972 · doi:10.2174/138920112799361972
  45. Oudshoorn, 2017, Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder, Hum Reprod., 32, 2506, 10.1093/humrep/dex319 · doi:10.1093/humrep/dex319
  46. Sopa, 2019, An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI, Eur J Obstet Gynecol Reprod Biol., 237, 42, 10.1016/j.ejogrb.2019.02.001 · doi:10.1016/j.ejogrb.2019.02.001
  47. Broer, 2011, AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis, Hum Reprod Update., 17, 46, 10.1093/humupd/dmq034 · DOI · Paper page
  48. Allegra, 2017, A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles, Reprod Biomed Online., 34, 429, 10.1016/j.rbmo.2017.01.012 · DOI
  49. Galindo, 2009, Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial, Gynecol Endocrinol., 25, 60, 10.1080/09513590802404013 · DOI
  50. Youssef, 2014, Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology, Cochrane Database Syst Rev., CD008046
  51. Burks, 2015, Can highly sensitive antimüllerian hormone testing predict failed response to ovarian stimulation?, Fertil Steril, 104, 643, 10.1016/j.fertnstert.2015.06.018 · doi:10.1016/j.fertnstert.2015.06.018
  52. Morin, 2018, Diminished ovarian reserve and poor response to stimulation in patients < 38 years old: a quantitative but not qualitative reduction in performance, Hum Reprod., 33, 1489, 10.1093/humrep/dey238 · DOI · Paper page
  53. Jaswa, 2021, Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity, Fertil Steril., 115, 966, 10.1016/j.fertnstert.2020.10.051 · DOI · Paper page
  54. Haahr, 2019, Management strategies for POSEIDON groups 3 and 4, Front Endocrinol (Lausanne)., 10, 614, 10.3389/fendo.2019.00614 · DOI
  55. Tal, 2021, AMH highly correlates with cumulative live birth rate in women with diminished ovarian reserve independent of age, J Clin Endocrinol Metab., 106, 2754, 10.1210/clinem/dgab168 · doi:10.1210/clinem/dgab168
  56. Legro, 2014, Letrozole versus clomiphene for infertility in the polycystic ovary syndrome, N Engl J Med., 371, 119, 10.1056/NEJMoa1313517 · DOI · Paper page
  57. Tranoulis, 2018, Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis, Fertil Steril., 109, 708, 10.1016/j.fertnstert.2017.12.028 · DOI
  58. Dumont, 2016, Comparison between pulsatile GnRH therapy and gonadotropins for ovulation induction in women with both functional hypothalamic amenorrhea and polycystic ovarian morphology, Gynecol Endocrinol., 32, 999, 10.1080/09513590.2016.1191462 · DOI
  59. Zawadski, 1992, Diagnostic criteria for polycystic ovary syndrome: towards a rational approach., 377
  60. Azziz, 2006, Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature, J Clin Endocrinol Metab., 91, 781, 10.1210/jc.2005-2153 · DOI · Paper page
  61. Pigny, 2006, Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome, J Clin Endocrinol Metab., 91, 941, 10.1210/jc.2005-2076 · DOI · Paper page
  62. Eilertsen, 2012, Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?, Hum Reprod., 27, 2494, 10.1093/humrep/des213 · DOI · Paper page
  63. Quinn, 2017, Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold, Clin Endocrinol (Oxf)., 87, 733, 10.1111/cen.13415 · DOI
  64. Mumford, 2016, Baseline AMH level associated with ovulation following ovulation induction in women with polycystic ovary syndrome, J Clin Endocrinol Metab., 101, 3288, 10.1210/jc.2016-1340 · DOI
  65. Zarek, 2016, Antimüllerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial, Fertil Steril., 105, 946, 10.1016/j.fertnstert.2015.12.003 · DOI
  66. Dólleman, 2015, Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study, Hum Reprod., 30, 1974, 10.1093/humrep/dev145 · DOI · Paper page
  67. de Kat, 2019, Can menopause prediction be improved with multiple AMH measurements? results from the prospective Doetinchem Cohort Study, J Clin Endocrinol Metab., 104, 5024, 10.1210/jc.2018-02607 · DOI
  68. Finkelstein, 2020, Antimullerian hormone and impending menopause in late reproductive age: the Study of Women’s Health Across the Nation, J Clin Endocrinol Metab., 105, e1862, 10.1210/clinem/dgz283 · DOI
  69. Skillern, 2008, Recent developments in identifying genetic determinants of premature ovarian failure, Sex Dev., 2, 228, 10.1159/000152039 · DOI
  70. Bilgin, 2015, Genetics of premature ovarian failure, Curr Opin Obstet Gynecol., 27, 167, 10.1097/GCO.0000000000000177 · DOI
  71. Mersereau, 2008, Luteal phase estrogen is decreased in regularly menstruating older women compared with a reference population of younger women, Menopause., 15, 482, 10.1097/gme.0b013e31815982cf · DOI
  72. Tran, 2011, The role of anti-müllerian hormone (AMH) in assessing ovarian reserve, J Clin Endocrinol Metab., 96, 3609, 10.1210/jc.2011-0368 · DOI
  73. Bry-Gauillard, 2017, Anti-Müllerian hormone and ovarian morphology in women with isolated hypogonadotropic hypogonadism/Kallmann syndrome: effects of recombinant human FSH, J Clin Endocrinol Metab, 102, 1102, 10.1210/jc.2016-3799 · doi:10.1210/jc.2016-3799
  74. Kallio, 2013, Antimüllerian hormone levels decrease in women using combined contraception independently of administration route, Fertil Steril., 99, 1305, 10.1016/j.fertnstert.2012.11.034 · DOI
  75. Birch Petersen, 2015, Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan, Hum Reprod., 30, 2364, 10.1093/humrep/dev197 · DOI
  76. Amer, 2020, Assessment of circulating anti-Müllerian hormone in women using hormonal contraception: a systematic review, J Womens Health (Larchmt)., 29, 100, 10.1089/jwh.2019.7733 · DOI
  77. Bernardi, 2021, Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels, Fertil Steril., 116, 208, 10.1016/j.fertnstert.2021.02.007 · DOI
  78. Landersoe, 2020, Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives, Reprod Biomed Online., 40, 176, 10.1016/j.rbmo.2019.10.004 · DOI
  79. Letourneau, 2017, Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer, Hum Reprod., 32, 2123, 10.1093/humrep/dex276 · DOI
  80. Steiner, 2010, Antimullerian hormone and obesity: insights in oral contraceptive users, Contraception., 81, 245, 10.1016/j.contraception.2009.10.004 · DOI
  81. Moslehi, 2018, Is ovarian reserve associated with body mass index and obesity in reproductive aged women? a meta-analysis, Menopause., 25, 1046, 10.1097/GME.0000000000001116 · DOI
  82. Jaswa, 2020, Increased body mass index is associated with a nondilutional reduction in antimüllerian hormone, J Clin Endocrinol Metab., 105, 3234, 10.1210/clinem/dgaa436 · DOI

Cited by

See all 208

Metadata

Authors
Cedars, M. I.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2022-02-01
Volume
107
Issue
6
Pages
1510-1519
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4210281782
Cited by
208
References
7
FWCI
26.66
Type
journal article
Language
en
Open access
bronze
Funders
Ferring Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Female Fertility—AMH and Ovarian Reserve Testing. https://app.cochat.ai/papers/10.1210/clinem/dgac039
The paper
Cedars, M. I. (2022). Evaluation of Female Fertility—AMH and Ovarian Reserve Testing. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.